TG Therapeutics Inc (NASDAQ:TGTX)

16.23
Delayed Data
As of Apr 24
 -0.18 / -1.10%
Today’s Change
4.42
Today|||52-Week Range
20.00
+2.46%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Biotechnology
MARKET CAP
$763.8M

Company Description

TG Therapeutics, Inc. is an innovative, clinical-stage biopharmaceutical company. It is focused on the acquisition, development and commercialization of innovative and medically important pharmaceutical products for the treatment of cancer and other underserved therapeutic needs. The company develops two therapies targeting hematological malignancies: TG-1101 and TGR-1202. The TG-1101 ublituximab is a novel, third generation monoclonal antibody that targets a specific and unique epitope on the CD20 antigen found on mature B-lymphocytes. The TGR-1202, is an orally available PI3K delta inhibitor. It also valuates complementary products, technologies and companies for in-licensing, partnership, acquisition and/or investment opportunities. TG Therapeutics was founded by Michael S. Weiss on May 18, 1993 and is headquartered in New York, NY.

Contact Information

TG Therapeutics, Inc.
3 Columbus Circle
New York New York 10019
P:(212) 554-4484
Investor Relations:
(212) 554-4351

Employees

Shareholders

Other institutional23.64%
Mutual fund holders17.82%
Individual stakeholders10.27%

Top Executives

Michael S. WeissExecutive Chairman, President & CEO
Sean A. PowerChief Financial Officer, Treasurer & Secretary
Robert NiecestroExecutive Vice President-Clinical & Regulatory
Hari MiskinHead-Business Development
Jenna A. BoscoDirector-Investor Relations

To view my watchlist

Not a member yet?

Sign up now for a free account